VIVUS Inc. (VVUS)
-NasdaqGS | Prev Close: | 14.50 |
|---|
| Open: | N/A |
|---|
| Bid: | 14.30 x 300 |
|---|
| Ask: | 14.88 x 700 |
|---|
| 1y Target Est: | 17.50 |
|---|
| Beta: | 1.08 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 9.86 - 31.21 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 2,551,460 |
|---|
| Market Cap: | 1.46B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.74 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Novo obesity drug could launch in U.S. end 2014at Reuters(Fri 6:20AM EDT)
- Vivus Heats Up, Shorts Discouraged On Possible Bidding Warat Seeking Alpha(Fri 5:41AM EDT)
- Arena - Good Sales, Bad Sales, Long And Shortat Seeking Alpha(Fri 2:53AM EDT)
- First Manhattan Still Playing Hardball With Vivusat Seeking Alpha(Fri 12:06AM EDT)
- Denner added as nominee to Vivus board by activist investorat Reuters(Thu, May 23)
- Bullish Two Hundred Day Moving Average Cross - VVUSat TheStreet(Thu, May 23)
- [video] Options Activity Ahead of Pandora Earningsat CNBC(Thu, May 23)
- Why This Obesity Drug Is the Sector's Best Betat Motley Fool(Thu, May 23)
- [video] Nasdaq Check: Tech Stocks Recoverat CNBC(Thu, May 23)
- Alex Denner Joins Vivus Activist Slate in Post-Icahn Moveat Bloomberg(Thu, May 23)
- InPlay: Vivus: First Manhattan adds Alex Denner to Vivus Board slate; Denner's Sarissa Capital Management owns 2 mln Vivus sharesBriefing.com(Thu, May 23)
- First Manhattan Adds Alex Denner to Vivus Board SlateBusiness Wire(Thu, May 23)
- 3 Pipeline Obesity Treatments You Should Watchat Motley Fool(Wed, May 22)
- VIVUS Announces Scientific PresentationsGlobeNewswire(Wed, May 22)
- Arena Pharmaceuticals - Out To Launch Or Out To Lunch?at Seeking Alpha(Wed, May 22)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 238.35 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.90 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.44 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | -0.13 |
|---|
Business Summary
VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health.
View More